Category: 3. Business

• Transaction strengthens balance sheet and liquidity with cash proceeds of $1.15 billion before customary closing adjustments

HOUSTON and LONDON, Jan. 05, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR, “the Company”), an energy technology company, announced Monday the successful closing of the sale of its Precision Sensors & Instrumentation (PSI) product line to Crane Company (NYSE: CR, “Crane”). PSI includes the Druck, Panametrics and Reuter-Stokes brands, and the Company had announced the divesture in July 2025.

With the recently announced formation of a joint venture for its surface pressure control product line, these transactions represent an important milestone in Baker Hughes’ value-creation strategy, reinforcing the Company’s commitment to disciplined portfolio management, operational execution and capital efficiency. The transactions enhance earnings and cash flow durability, enable the redeployment of capital toward higher-return opportunities, and provide cash proceeds to further strengthen the balance sheet, all within a rigorous, returns-focused approach to capital allocation.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Media Relations

Adrienne M. Lynch+1 713-906-8407
adrienne.lynch@bakerhughes.com 

Investor Relations

Chase Mulvehill+1 346-297-2561
investor.relations@bakerhughes.com 

Source: Baker Hughes

Efforts by Telford and Wrekin Council to reduce its carbon emissions are ahead of target but further reductions are becoming “more challenging”, according to the authority.

In 2019 the council was among many authorities to declare a “climate emergency” and set out a target to become carbon neutral by 2030.

A council report said that by the end of March 2025, emissions had been reduced by 63% since 2018/19, thanks to a range of measures in homes, leisure centres, and offices. The authority said that put it eight per cent ahead of where it was expecting to be at this stage.

The council has set itself a target of reaching a 70 per cent reduction by 2026/27.

“We have made strong progress in reducing the council’s emissions so far, but we recognise that it is getting harder and more challenging to do,” the report stated.

Measures taken include making homes more energy-efficient and increasing the number of solar panels on council buildings.

The council owns the Wheat Leasows solar farm which last year produced 3,144 MWh of electricity, enough energy to power 1,084 homes.

It said it was looking at the possibility of more solar energy and improving connections to the national electricity network.

In addition, the authority said it was taking measures to prepare the area for the impact of climate change.

It said risks included damage to roads and trees from flooding, heat and wind, with heat also recognised as a threat to public health and the smooth running of IT systems.

With the rise of AI summaries for health information and the introduction of AI mode, a group of health charities, including the BHF, have raised concerns about access to trustworthy information. 

The charities, including end of life charity Marie Curie, the Patient Information Forum (PIF), Macmillan Cancer Support, Cancer Research UK and us, have urged the public to look beyond AI health summaries and visit trusted, evidence-based, UK-verified sources for additional information and context.

A report from Marie Curie, Macmillan and PIF, which represents health organisations, published earlier this year raised concerns over AI-generated health summaries on search engines such as Google.

Concerns highlighted by organisations include:

• Gynae cancer charity The Eve Appeal highlighted that a search for ‘vaginal cancer symptoms and tests’ produced an AI summary that listed a PAP test as a test for vaginal cancer, which is incorrect.     
• An AI-generated summary advised people with pancreatic cancer to avoid high-fat foods. However, Pancreatic Cancer UK said this advice is the opposite of recommendations for people affected by pancreatic cancer. 
• Searches for information on what a ‘normal’ range is for liver blood tests returned AI-generated summaries which don’t account for a person’s sex, age or ethnicity. The British Liver Trust said this made the information inaccurate for some people.

These concerns arise as a recent survey of PIF members revealed that almost half (49%) have seen inaccuracies or misinformation about their topic area in AI overviews.

More than 6 out of 10 health charities have observed a decline in traffic to their websites since the rollout of health summaries.

This has sparked concerns that the public is not accessing source information and could be missing out on vital additional professional support and context when it is most needed. 

The coalition is calling on Google and other search engine providers to take immediate action to reduce potential harm, including:

• Clear signposting to NHS-approved advice and support services
• Prioritised verified UK-based sources with links to further information
• Clear disclaimers that AI-generated content cannot substitute medical advice.

Dr Charmaine Griffiths, our Chief Executive, said: “Being diagnosed with cardiovascular disease is one of those moments in life where having access to need reliable, evidence-based information and advice is priceless.

“Each year millions of heart patients and their families turn to the internet in search of answers to their questions, and we have a duty as a society to ensure they access only the highest quality information and advice online.

“This is why it is so vital that verified sources such as the BHF website remain a first port of call for those in need of trustworthy, unbiased and accurate information about heart disease.” 

Sophie Randall, Director of the Patient Information Forum, said: “We know there are concerns about the results in some AI Overview results. PIF has a mission to promote trusted health information to the public, which is why we are making our report available to the public. 

“To stay safe when searching for health information online, we encourage the public to use trusted sources such as www.nhs.uk, look for the PIF TICK, the UK’s only quality mark for reliable health content, and add ‘UK’ to their searches to help surface relevant, UK-based information.” 

HOW WE CREATE OUR HEALTH INFORMATION

The latest UK weather forecast: Snow flurries to ease but cold days aheadpublished at 10:03 GMT

10:03 GMT

Sarah Keith-Lucas
Broadcast Meteorologist, BBC Weather

Cold Arctic air remains
across all parts of the UK today.

Further snow showers are
expected for areas exposed to the northerly winds, especially northern
Scotland, Northern Ireland, west Wales, south-west England and parts of eastern
England.

The Met Office has issued various yellow warnings for snow and ice warnings
in these regions.

While many places will
stay dry with wintry sunshine, it will feel cold with icy stretches for all.
Maximum temperatures will reach just -2C across parts of Scotland, and
typically 1 to 3C elsewhere.

Most snow flurries will
gradually ease away later this afternoon and evening, to leave a cold
night with a sharp frost and ice.

Tuesday will turn a
little milder, but further hill snow is possible over the higher ground of
Scotland and northern England.

Later in the day and through the night, another
area of rain, sleet and hill snow will affect the southern half of the UK.

Any
snowfall by Tuesday is not expected to be as heavy or disruptive as it has been
over the past few days.

As a reminder, you can check the forecast for your area on BBC Weather.

Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme’s ENHANZE^® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye’s evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes.

“Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market, a therapeutic area with significant long-term potential,” said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. “This agreement reinforces the scalability of ENHANZE across diverse indications and supports our strategy to drive sustainable royalty growth with new partnerships and innovations.”

“To fully evaluate nimacimab’s potential, we need to test higher doses and we need a practical way to deliver them subcutaneously,” said Punit Dhillon, President and Chief Executive Officer of Skye. “Partnering with Halozyme to co-formulate nimacimab with ENHANZE gives us a validated approach to evaluate multiple dose-ranging strategies, including in combination with GLP-1 receptor agonists.”

Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE^® for at least 10 years.

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

As the innovators of ENHANZE^® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE^® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.

Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.

Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex^® and XYOSTED^®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit http://www.halozyme.com and connect with us on LinkedIn and Twitter.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy^®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

Forward-Looking Statements 

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, potential new partnerships and innovations, the possible activity, benefits and attributes of ENHANZE^®, the possible method of action of ENHANZE^®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE^® including facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery and potentially lowering the treatment burden and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of Skye (including the potential regulatory approval and launch of nimacimab as a result of such efforts and the potential future market opportunity for such products) and Halozyme’s potential receipt of payments associated with achievement of certain development, regulatory and sales-based milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme and Skye’s most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme and Skye undertake no duty to update forward-looking statements to reflect events after the date of this release.

Contacts

Halozyme
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]

Skye Investor & Media Relations
[email protected]
(858) 410-0266

LifeSci Advisors
Mike Moyer
[email protected]
(617) 308-4306

SOURCE Halozyme Therapeutics, Inc.

FRANKLIN LAKES, N.J., Jan. 5, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix™ Mesh laparotomy reinforcement case performed in Greece following the product’s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union.

The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix™ Mesh (08 x 30 cm) was placed prophylactically at the laparotomy incision site to reduce the likelihood of future hernia development.

Concurrently, BD’s PREVENT multicenter randomized controlled trial, conducted across sites in both Europe and the United States, has treated over 85% of its target population and is projected to complete enrollment in 2026. The study aims to provide robust clinical evidence supporting prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias, while also supporting PMA submission for an incisional hernia prevention indication in the United States.

“Incisional hernias affect up to 30% of patients after abdominal surgery and cost health care systems billions annually,” said Rian Seger, worldwide president of the BD Surgery business. “With Phasix™ Mesh, we’re not just repairing hernias—we’re preventing them. This milestone reflects our commitment to improving long-term patient outcomes.”

According to recent U.K. data, patients who undergo incisional hernia repair incur an average cost of £23,148—nearly double that of patients who do not require repair. Prevention strategies have the potential to significantly reduce these costs and improve patient quality of life.

Phasix™ Mesh received CE marking approval for the prophylactic indication and launched three new sizes in 2025. The product is now registered in the U.K. and available across Europe for broad hernia prophylaxis indications, marking a pivotal step toward redefining surgical best practices, helping clinicians deliver safer outcomes and improve efficiency in every procedure. Phasix™ Mesh is not indicated for use for hernia prevention in the United States.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

 

SOURCE BD (Becton, Dickinson and Company)

HOUSTON and LONDON, Jan. 05, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB), a leader in the global chemical industry, will announce its fourth-quarter 2025 financial results before the U.S. market opens Friday, Jan. 30, followed by a webcast and teleconference to discuss the results at 11 a.m. EST.

Teleconference and webcast details
Friday, January 30, 2026
11 a.m. EST
Hosted by David Kinney, head of investor relations
Access the webcast 10 to 15 minutes prior to the start of the call at www.lyb.com/earnings.

Toll-free teleconference dial-in numbers
Participant/Guest toll-free: 877-407-8029
Participant/Guest toll: 201-689-8029
Participant/Guest: CallMe link

Presentation slides
Presentation slides will be available at the time of the teleconference and afterward at www.lyb.com/earnings.

Replay information
A replay of the call will be available from 1 p.m. EST Jan. 30 until March 2, 2026. The replay dial-in numbers are:
Toll-Free: 877-660-6853
Toll: 201-612-7415
Access ID: 13746215

About LyondellBasell 
We are LyondellBasell (NYSE: LYB) – a leader in the global chemical industry creating solutions for everyday sustainable living. Through advanced technology and focused investments, we are enabling a circular and low carbon economy. Across all we do, we aim to unlock value for our customers, investors and society. As one of the world’s largest producers of polymers and a leader in polyolefin technologies, we develop, manufacture and market high-quality and innovative products for applications ranging from sustainable transportation and food safety to clean water and quality healthcare. For more information, please visit www.lyondellbasell.com or follow @LyondellBasell on LinkedIn.

CONTACT: Nick Facchin
LyondellBasell
713-623-3643
nick.facchin@lyondellbasell.com